Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations
A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar®) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- Open-label, single-arm, prospective pilot study.
- Definition of advanced non small cell lung cancer: stage IIIb or IV. EGFR mutation status: activating mutation (defined as deletion 19 or exon 21 L858R mutation).
- Before starting study treatment, computed tomography scans of the chest, B ultrasound of abdomen, 12-lead electrocardiogram, MRI scan of brain, and a bone scan are required.
- Tumor response, based on investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST v.1.1), will be evaluated every 6 weeks during treatment.
- Exploratory evaluation will be performed using dynamic contrast enhanced MRI (DCE-MRI).
- QoL will be assessed using the core module, which will be completed by patients at baseline and before each cycle during treatment.
- All patients who prematurely discontinue treatment for any reason will be followed for survival.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Recruiting
- Zhejiang University
-
Contact:
- Qiong Zhao
- Phone Number: 0571-87236802
- Email: doczq.2008@gmail.com
-
Contact:
- Ling Peng
- Phone Number: 0571-87236800
- Email: Drpengling@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic documentation of non small cell lung cancer, with activating epidermal growth factor receptor (defined as deletion 19 or exon 21 L858R mutation).
- Stage IV disease according to the 7th Edition of the American Joint Committee on Cancer staging system -Measureable disease
- Life expectancy of >= 12 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- Absolute neutrophil count (ANC) >= 1, 500/mm^3, platelet count >= 100,000/mm^3, hemoglobin >= 9.0 g/dL.
- Total bilirubin =< 1.5 x upper limit of normal (ULN), serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN in patients without liver or bone metastases; < 5 x ULN in patients with liver or bone metastases, cockcroft-Gault calculated creatinine clearance of >= 45 ml/min or creatinine =< 1.5 x ULN.
- Prothrombin time (PT) =< 1.5 x ULN, partial thromboplastin time (PTT) =< ULN
- Urine dipstick proteinuria < 2+. Patients discovered to have >= 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.
- Negative pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only.
- Provide informed written consent.
- Willing to return to enrolling institution for follow-up.
- Willing to provide tissue and blood samples for correlative research purposes.
Exclusion Criteria:
- Evidence of bleeding diathesis or coagulopathy.
- Evidence of central nervous system involvement or brain metastases confirmed by head CT or brain MRI within 28 days prior to being registered for protocol therapy.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for protocol therapy.
- Anticipation of need for major surgical procedure during the course of the study.
- Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to registration for protocol therapy.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for protocol therapy.
- Serious, non-healing wound, ulcer, or bone fracture.
- History of hemoptysis.
- Clinically significant infections as judged by the treating investigator.
- Other active malignancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Endostar and icotinib
Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po.
If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.
|
Endostar and icotinib are used as combination therapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective response rate
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression free survival
Time Frame: 12 months
|
12 months
|
|
|
Safety: Number of Participants with Adverse Events
Time Frame: 12 months
|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostar protein
- Endostatins
Other Study ID Numbers
Other Study ID Numbers
- ZYTOP1501
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.